ALNY

Alnylam Pharmaceuticals
D

ALNY

250.450
USD
-0.48
(-0.19%)
مغلق
حجم التداول
14,005
الربح لكل سهم
0
العائد الربحي
-
P/E
-115
حجم السوق
32,422,544,720
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    AMGN
    AMGN
    5.10
    (1.71%)
    303.15 USD
    A
    ARWR
    -1.040
    (-4.97%)
    19.900 USD
    BIIB
    BIIB
    3.560
    (2.60%)
    140.630 USD
    C
    CRSP
    -2.620
    (-5.19%)
    47.840 USD
    E
    EDIT
    -0.14000
    (-6.80%)
    1.92000 USD
    GILD
    GILD
    -0.140
    (-0.13%)
    109.920 USD
    MRNA
    MRNA
    1.785
    (5.29%)
    35.535 USD
    REGN
    REGN
    4.37
    (0.63%)
    700.66 USD
    VRTX
    VRTX
    4.10
    (0.85%)
    484.53 USD
    المزيد
الأخبار
المقالات

العنوان: Alnylam Pharmaceuticals

القطاع: Healthcare
الصناعة: Biotechnology
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.